Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230542 · ClinicalTrials.gov registry record · Phase 2
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00230542 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 44 participants.
The verdict
NCT00230542, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230542
The ClinicalTrials.gov registry entry for NCT00230542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT00230542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230542 about?
NCT00230542 is a clinical study titled "Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer". The purpose of this study is to determine the effects (good and bad) the combination of carboplatin and pemetrexed have on patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
What is the current status of trial NCT00230542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2005-09. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00230542?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00230542?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.